A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-β1 in the development of myelofibrosis

被引:96
作者
Vannucchi, AM
Bianchi, L
Paoletti, F
Pancrazzi, A
Torre, E
Nishikawa, M
Zingariello, M
Di Baldassarre, A
Rana, RA
Lorenzini, R
Alfani, E
Migliaccio, G
Migliaccio, AR
机构
[1] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy
[2] Ist Super Sanita, Dept Hematol, I-00161 Rome, Italy
[3] Ist Super Sanita, Dept Oncol, I-00161 Rome, Italy
[4] Ist Super Sanita, Dept Mol Med, I-00161 Rome, Italy
[5] Univ Florence, Dept Hematol, Florence, Italy
[6] Univ Florence, Dept Expt Pathol & Oncol, Florence, Italy
[7] Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma, Japan
[8] Univ Chieti, Dept Biomorphol, Rome, Italy
关键词
D O I
10.1182/blood-2004-04-1320
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic myelofibrosis (IM) is a disease characterized by marrow fibrosis, abnormal stem/progenitor cell trafficking, and extramedullary hematopoiesis frequently associated with alterations in megakaryocytes (Mks). Mice harboring genetic alterations in either the extrinsic (ectopic thrombopoietin expression, TPOhigh mice) or intrinsic (hypomorphic GATA-1 mutation, GATA-1(low) mice) control of Mk differentiation develop myelofibrosis, a syndrome similar to IM. The relationship, if any, between the pathofibrologic mechaand spleen. Surprisingly, TPO treatment of GATA-1(low) mice restored the GATA-1 content in Mks and halted both defective thrombocytopoiesis and fibrosis. These data indicate that the TPOhigh and GATA1(low) alterations are linked in an upstream-downstream relationship along a pathobiologic pathway leading to development of myelofibrosis in mice and, possibly, of IM in humans. (c) 2005 by The American Society of Hematology.
引用
收藏
页码:3493 / 3501
页数:9
相关论文
共 39 条
[1]   Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].
Barosi, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2954-2970
[2]   Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis [J].
Beham-Schmid, C ;
Apfelbeck, U ;
Sill, H ;
Tsybrovsky, O ;
Höfler, G ;
Haas, OA ;
Linkesch, W .
BLOOD, 2002, 99 (01) :381-383
[3]  
Castro-Malaspina H, 1984, Prog Clin Biol Res, V154, P427
[4]   Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice [J].
Centurione, L ;
Di Baldassarre, A ;
Zingariello, M ;
Bosco, D ;
Gatta, V ;
Rana, RA ;
Langella, V ;
Di Virgilio, A ;
Vannucchi, AM ;
Migliaccio, AR .
BLOOD, 2004, 104 (12) :3573-3580
[5]   Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice [J].
Chagraoui, H ;
Komura, E ;
Tulliez, M ;
Giraudier, S ;
Vainchenker, W ;
Wendling, F .
BLOOD, 2002, 100 (10) :3495-3503
[6]   Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1 [J].
De Maria, R ;
Zeuner, A ;
Eramo, A ;
Domenichelli, C ;
Bonci, D ;
Grignani, F ;
Srinivasula, SM ;
Alnemri, ES ;
Testa, U ;
Peschle, C .
NATURE, 1999, 401 (6752) :489-493
[7]   Allogeneic hematopoietic stem cell transplantation for myelofibrosis [J].
Deeg, HJ ;
Gooley, TA ;
Flowers, MED ;
Sale, GE ;
Slattery, JT ;
Anasetti, C ;
Chauncey, TR ;
Doney, K ;
Georges, GE ;
Kiem, HP ;
Martin, PJ ;
Petersdorf, EW ;
Radich, J ;
Sanders, JE ;
Sandmaier, BM ;
Warren, EH ;
Witherspoon, RP ;
Storb, R ;
Appelbaum, FR .
BLOOD, 2003, 102 (12) :3912-3918
[8]   Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia [J].
Devine, SM ;
Hoffman, R ;
Verma, A ;
Shah, R ;
Bradlow, BA ;
Stock, W ;
Maynard, V ;
Jessop, E ;
Peace, D ;
Huml, M ;
Thomason, D ;
Chen, YH ;
van Besien, K .
BLOOD, 2002, 99 (06) :2255-2258
[9]   GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling [J].
Grass, JA ;
Boyer, ME ;
Pal, SM ;
Wu, J ;
Weiss, MJ ;
Bresnick, EH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) :8811-8816
[10]   Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia [J].
Guardiola, P ;
Esperou, H ;
CazalsHatem, D ;
Ifrah, N ;
Jouet, JP ;
Buzyn, A ;
Sutton, L ;
Gratecos, N ;
Tilly, H ;
Lioure, B ;
Gluckman, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (04) :1004-1009